Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT) for Prostate Cancer (Fez-Cap)

NCT07568236 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT07568236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07568236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT) for Prostate Cancer (Fez-Cap)
Lead sponsor
Chinese University of Hong Kong
Phase
Phase 2
Overall status
Recruiting
Start date
October 5, 2026
Completion date
March 31, 2028
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, vasomotor symptoms